Overall , 90/105 ( 86 % ) patients ( 46/53 tenofovir and 44/52 emtricitabine/tenofovir ) completed the 168-week study period , including 74/105 ( 70 % ) patients ( 35/53 tenofovir and 39/52 emtricitabine/tenofovir ) who completed the study on their initial randomized treatment .